BioCentury
ARTICLE | Company News

Management tracks: Mirum, Novocure

March 22, 2019 9:19 PM UTC

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018 with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases (see "Mirum Launches With Liver Disease Candidates from Shire").

Cancer company Novocure Ltd. (NASDAQ:NVCR) said CSO and Head of R&D Eilon Kirson will step down, effective May 1. VP of Clinical Development Uri Weinberg will assume responsibilities for preclinical and clinical development, as well as regulatory affairs. Novocure also hired Ely Benaim as CMO, effective April 1. He was CMO of Rexahn Pharmaceuticals Inc. (NYSE-A:RNN)...